ArticleBMC medical imaging2025
Multiparametric MRI for differential diagnosis of primary central nervous system lymphoma and atypical glioblastoma: an analysis incorporating DWI, DCE-MRI, and contrast agent preload DSC-PWI.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prediction of relapsed/refractory primary central nervous system lymphoma using pre-chemotherapy ITSS grade on SWI and pre-/post-chemotherapy ADC parameters on DWI.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThe differential diagnosis of primary central nervous system lymphoma (PCNSL) and atypical glioblastoma (aGBM) exhibiting homogeneous enhancement and negligible necrosis poses a significant challenge for conventional MRI. The study aims to investigate diffusion-weighted imaging (DWI), dynamic contrast-enhanced (DCE) MRI, and contrast agent (CA) preload dynamic susceptibility contrast perfusion-weighted imaging (DSC-PWI) to differentiate aGBM and PCNSL. MATERIALS AND
methodsThis retrospective study analyzed 27 patients with aGBM (solid enhancement without visible necrosis) and 105 patients with PCNSL, all undergoing preoperative DWI, DCE-MRI, and CA preload DSC-PWI. The relative apparent diffusion coefficient (rADC) and relative cerebral blood volume (rCBV) were obtained from DWI and DSC-PWI. The pharmacokinetic parameters (Ktrans, Ve, Kep, and iAUC) were acquired using DCE-MRI. The independent-samples t-test and Mann-Whitney U test were utilized to compare parameters. A binary logistic regression analysis was performed to assess the combined effect of various parameters. Before regression analysis, collinearity analysis of parameters was performed. The diagnostic capability of each parameter and their combination were evaluated by receiver operating characteristic (ROC) with area under the curve (AUC) and compared with DeLong test.
resultsIn comparison to aGBM, the Ktrans, Ve, and iAUC were significantly elevated in PCNSL, whereas the rCBV and rADC were significantly lower (p < 0.05 for all comparisons). Meanwhile, these parameters allowed excellent diagnostic performance (AUC = 0.817 [rCBV], 0.751 [rADC], 0.808 [Ktrans], 0.765 [Ve], and 0.801 [iAUC]; DeLong test, p > 0.05 for all comparisons). Notably, the combination of all these parameters significantly increased the probability of distinguishing aGBM from PCNSL (AUC = 0.966).
conclusionsDWI, DCE-MRI, and CA preload DSC-PWI can effectively differentiate aGBM from PCNSL, and the combination of all three techniques significantly enhances the discriminatory efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.